Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $19.67 USD
Change Today +0.13 / 0.67%
Volume 62.2K
LJPC On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/15 - $24.89
52 Week Low
10/13/14 - $7.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company engages in developing LJPC-501, an angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome; and GCS-100, a galectin-3 inhibitor for the potential treatment of chronic kidney disease. It also develops LJPC-1010 galectin-3 inhibitor for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis; and LJPC-401, a hepcidin for the potential treatment of hemochromatosis and beta thalassemia. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

25 Employees
Last Reported Date: 03/16/15
Founded in 1989

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $705.0K
Compensation as of Fiscal Year 2014.

la jolla pharmaceutical co (LJPC) Key Developments

La Jolla Pharmaceutical Co. - Special Call

To discuss acquisition and portfolio reprioritization

La Jolla Pharmaceutical Co. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

La Jolla Pharmaceutical Co. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $8,966,000 and net loss and comprehensive loss of $8,955,000 or $0.59 per basic and diluted share against loss from operations of $5,130,000 and net loss and comprehensive loss of $5,128,000 or $0.93 per basic and diluted share reported for the same period a year ago. The increase in net loss was primarily due to increased clinical development costs associated with the initiation of ATHOS 3 trial, the initiation of Phase 2b clinical trial of GCS-100 in advanced CKD, the continuing Phase 1/2 clinical trial of LJPC-501 in HRS and preclinical costs associated with LJPC-1010 and LJPC-401, as well as increases in personnel and related costs, which were mainly due to additional headcount to support such increased development activities.

La Jolla Pharmaceutical Co. Appoints Lakhmir S. Chawla as Chief Medical Officer, Effective July 1, 2015

La Jolla Pharmaceutical Co. announced that Lakhmir S. Chawla, M.D., will be joining the company as Chief Medical Officer, effective July 1, 2015. Dr. Chawla is currently an Associate Professor of Medicine at the George Washington University, where he has dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla is also currently the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $19.67 USD +0.13

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies

Industry Analysis


Industry Average

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at